VTE Risk High in Cancer Patients Receiving Immune Checkpoint Inhibitors
History of VTE predicts VTE occurrence; VTE occurrence linked to increased mortality
Thromboembolism
High Incidence of Thrombotic Complications, Lower Mortality in the Second Wave of Patients With COVID-19
Researchers sought to assess the incidence of thrombotic complications in the second wave of patients with COVID-19, how many patients had diagnostic imaging for these complications, overall mortality, and then compared these outcomes with the first wave.
Moderate to Severe CKD Shown to Worsen VTE Prognosis
In a study, patients with moderate to severe CKD vs mild or no CKD had increased risk for death and recurrent venous thromboembolism.
ASH: Rivaroxaban Prevents Blood Clots in At-Risk Cancer Patients
Risk for patients in rivaroxaban group reduced during the on-treatment period
Patient Education Ups VTE Prophylaxis in Hospital Setting
Targeted patient-centered intervention reduces nonadministration of pharmacologic prophylaxis.
Risk of Venous Thromboembolism Recurrence High
At 6 months, rates for provoked, unprovoked, cancer-related VTE are 6.8, 6.92, 9.06 per 100 person-years
Peri-Op RBC Transfusions Linked to Postoperative VTE
Perioperative red blood cell transfusion linked to increased adjusted odds of VTE, DVT, PE.
Reduced-Dose Anticoagulants Feasible for Extended VTE Tx
May be as effective as full-dose direct oral anticoagulants for extended-duration treatment.
Rivaroxaban Linked to Low VTE Recurrence in Active Cancer
Lower rate of VTE recurrence, but higher clinically relevant non-major bleeding versus dalteparin.
Pharmacomechanical Thrombolysis Does Not Cut Post-thrombotic Syndrome
Pharmacomechanical thrombolysis used with anticoagulation treatment, did not decrease post-thrombotic syndrome risks but increased major bleeding risks in patients with acute proximal DVT.
- Loading...
Loading...
Next post in Urology
Loading... 
Loading...